Hanmi Pharm Co.,Ltd. (Korean : 한미약품주식회사; Hanja : 韓美藥品株式會社) is a South Korean pharmaceutical company that is headquartered in Seoul. [1]
Hanmi was founded in 1973 by Lim Sung-ki,who was a pharmacist. [2] It was originally named Lim,Sung-ki Pharmaceutical Co.,but it was quickly changed to Hanmi Pharmaceutical. The company originally started selling Trimethoprim/sulfamethoxazole powder,and would expand to produce Cephalosporin antibiotics in 1985 and injectable Ceftriaxone antibiotics in 1987. By 1988 the company was listed in the Korea Exchange. [3] Hanmi started selling drugs in China in 1996. [4] In 1994,the company began developing Cyclosporin. The company broke the ₩ 100,000,000,000 barrier in sales in 1997. The company began moving into the European market in 1998. The company still was developing new drugs,with Paclitaxel in 2000,Itraconazole tablets in 2001,24-hour controlled-release Nifedipine tablets and a new salt form of Amlodipine in 2004,and an anti-obesity drug using sibutramine mesilate in 2007. Hanmi and Crystal Genomics formed a strategic partnership in 2008. [3]
By around 2010,Hanmi's R&D had two areas of interest:developing longer-lasting peptide and protein therapeutics using its "Lapscovery" technology,and developing small molecule tyrosine-kinase inhibitors for cancer and autoimmune diseases. Its strategy was to developmental incremental modifications of existing drugs,create new combination drugs,and to develop novel drugs. [5] [6]
In August 2014 Hanmi exclusively licensed rights in China for poziotinib,a small molecule EGFR inhibitor,to the Chinese company Luye Pharma;in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals. [5]
In March 2015 Hanmi and Lilly signed an exclusive license outside of Asia for Hanmi's small molecule Bruton's tyrosine kinase inhibitor in the field of autoimmune diseases;Lilly paid $50 million upfront and the deal included up to $640 million in milestones and royalties greater than 10%. [7]
In November 2015 Hanmi signed three agreements:
In April 2016 Hanmi announced that it had acquired land near Yantai in the Shandong province of China,where it would build a manufacturing plant and R&D facility;at that time it already had a facility in Beijing. [4] In July Hanmi said it intended to invest more heavily in developing candidate substances of promising new drugs at an early stage in new pharmaceutical and biotech related fields,including through a venture capital firm set up by Sung-ki and colleagues.
In May 2016 the Korean regulatory authority approved olmutinib as a second-line treatment for certain kinds of non-small cell lung cancer. [2]
On September 28 Hanmi and Zentec Pharmaceuticals agreed that Zentec would market Hanmi's small molecule cancer drug candidate,HM95573;Zentec paid $80 million upfront,with $830 million in milestones,and royalties. [10]
On September 29,Hanmi and Roche's cancer subsidiary Genentech announced a deal for Hanmi's Phase I cancer drug candidate,HM95573,which targets the MAPK/ERK pathway;Roche agreed to pay $80 million upfront,and the deal included $830 million in milestones. [11]
In December 2016 the Sanofi deal was reduced in scope,with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product,and agreeing to repay Sanofi $250 million of the $434 million upfront payment. [12]
On December 3,2019,Rapt Therapeutics and Hanami Pharmaceutical announced collaboration to develop and commercialize FLX475 in Asia. [13] FLX475 is an oral,small molecule CCR4 antagonist in development for the treatment of multiple cancers.
In August 2020,chairman and founder of Hanmi Pharmaceutical Lim Sung-ki died of a chronic disease. He was 80. [14]
On May 15,2023,Athenex,which was Hanmi's U.S. partner for its anticancer product,Oraxol,filed for Chapter 11 bankruptcy protection. [15]
On the evening of September 29,2016,Hanmi announced the Roche deal,causing its stock to rise;Hanmi was notified by Boehringer that evening that Boehringer was terminating their deal,and the company announced the termination on the morning of the 30th,causing its stock to crash. Hanmi's offices were raided by Korean regulatory authorities in mid-October based on evidence that insider knowledge of the Boehringer termination was passed to third parties,who shorted the stock prior to the announcement on the 30th. [1] [16] In December three Hanmi employees were among 17 people indicted for insider trading;25 people were fined,and 45 people were found to have made illegal trades that took around 3.3 billion won ($2.83 million) in profits based on the information. [17] [18]
On September 30,2016,Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis,one of which was fatal,and a case of Stevens–Johnson syndrome;Boeheringer announced the termination its deal with Hanmi the same day,citing that the decision came after a review of "all available clinical data" on the drug,and also referring to competing drugs. [19]
In April 2018 Hanmi was found to have violated two laws in Korea by not disclosing adverse effects of olmutinib sooner. [20] In that month Zai said it was dropping olmutinib [21] and a few days later Hanmi said it was terminating development of the drug. [22]
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia,behind Sinopharm and Shanghai Pharmaceuticals,and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology,rare diseases,neuroscience,gastroenterology,plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku,Osaka,and it has an office in Nihonbashi,Chuo,Tokyo. In January 2012,Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015,Christophe Weber was appointed as the CEO and president of Takeda.
Genentech,Inc. is an American biotechnology corporation headquartered in South San Francisco,California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically,the company is regarded as the world's first biotechnology company.
Biogen Inc. is an American multinational biotechnology company based in Cambridge,Massachusetts,United States specializing in the discovery,development,and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina,Brazil,Canada,China,France,Germany,Hungary,India,Italy,Japan,Mexico,Netherlands,Poland,Sweden,and Switzerland.
AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge,United Kingdom. It has a portfolio of products for major diseases in areas including oncology,cardiovascular,gastrointestinal,infection,neuroscience,respiratory,and inflammation.
F. Hoffmann-La Roche AG,commonly known as Roche,is a Swiss multinational holding healthcare company that operates worldwide under two divisions:Pharmaceuticals and Diagnostics. Its holding company,Roche Holding AG,has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023,the company’s seat in Forbes Global 2000 was 76.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris,France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004,Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis,which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023,the company’s seat in Forbes Global 2000 was 89.
C.H. Boehringer Sohn AG &Co. KG is the parent company of the Boehringer Ingelheim group,which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein,Germany. As of 2018,Boehringer Ingelheim is one of the world's largest pharmaceutical companies,and the largest private one. Headquartered in Ingelheim,it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed,the company is private and fully owned by the Boehringer,Liebrecht and von Baumbach families. The company's key areas of interest are:respiratory diseases,metabolism,immunology,oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen,Denmark. The company also had a branch in San Diego,California that opened in 2009. Created by a merger between Cureon and Pantheco,Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg,Germany. The company operates globally,largely through external alliances with pharmaceutical and biotechnology companies,academic institutions,patient advocacy groups,and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery,pre-clinical development and clinical development.
GTx,Inc. was a pharmaceutical company working on drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes. Its drugs in development included enobosarm (ostarine) and GTx-758.
Alnylam Pharmaceuticals,Inc. is an American biopharmaceutical company focused on the discovery,development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge,Massachusetts. In 2016,Forbes included the company on its "100 Most Innovative Growth Companies" list.
Samsung Biologics Co.,Ltd. is a global contract development and manufacturing organization headquartered in Songdo,Incheon,South Korea. The biotech division of Samsung Group,its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies,bispecific antibodies,antibody-drug conjugates,and mRNA vaccines.
Ionis Pharmaceuticals,Inc. is a biotechnology company based in Carlsbad,California,that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines:Spinraza (Nusinersen),Tegsedi (Inotersen),and Waylivra (Volanesorsen),and has four drugs in pivotal studies:tominersen for Huntington's disease,tofersen for SOD1-ALS,AKCEA-APO(a)-LRx for cardiovascular disease,and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
Insulin glargine/lixisenatide,sold under the brand name Soliqua among others,is a fixed-dose combination medication that combines insulin glargine and lixisenatide and is used to treat diabetes.
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Olmutinib (INN) is an investigational anti-cancer drug. It acts by covalently bonding to a cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles,CA.
Arrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham,Massachusetts,and was founded in 2015 by Jennifer Petter,now the company's Chief Innovation Officer. In October 2016,Michael Gilman,a former Biogen executive,was named CEO.
Gregory L. Verdine is an American chemical biologist,biotech entrepreneur,venture capitalist and university professor. He is a founder of the field of chemical biology,which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.